Literature DB >> 28258214

Identification of a feedback loop involving β-glucosidase 2 and its product sphingosine sheds light on the molecular mechanisms in Gaucher disease.

Sophie Schonauer1, Heinz G Körschen2, Anke Penno3, Andreas Rennhack2, Bernadette Breiden4, Konrad Sandhoff4, Katharina Gutbrod5, Peter Dörmann5, Diana N Raju1, Per Haberkant6, Mathias J Gerl7, Britta Brügger7, Hila Zigdon8, Ayelet Vardi8, Anthony H Futerman8, Christoph Thiele3, Dagmar Wachten9,10.   

Abstract

The lysosomal acid β-glucosidase GBA1 and the non-lysosomal β-glucosidase GBA2 degrade glucosylceramide (GlcCer) to glucose and ceramide in different cellular compartments. Loss of GBA2 activity and the resulting accumulation of GlcCer results in male infertility, whereas mutations in the GBA1 gene and loss of GBA1 activity cause the lipid-storage disorder Gaucher disease. However, the role of GBA2 in Gaucher disease pathology and its relationship to GBA1 is not well understood. Here, we report a GBA1-dependent down-regulation of GBA2 activity in patients with Gaucher disease. Using an experimental approach combining cell biology, biochemistry, and mass spectrometry, we show that sphingosine, the cytotoxic metabolite accumulating in Gaucher cells through the action of GBA2, directly binds to GBA2 and inhibits its activity. We propose a negative feedback loop, in which sphingosine inhibits GBA2 activity in Gaucher cells, preventing further sphingosine accumulation and, thereby, cytotoxicity. Our findings add a new chapter to the understanding of the complex molecular mechanism underlying Gaucher disease and the regulation of β-glucosidase activity in general.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Gaucher disease; glycerosphingolipid; lipid metabolism; lipid signaling; lipid-protein interaction

Mesh:

Substances:

Year:  2017        PMID: 28258214      PMCID: PMC5391749          DOI: 10.1074/jbc.M116.762831

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

2.  Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders.

Authors:  Maria J Ferraz; André R A Marques; Paulo Gaspar; Mina Mirzaian; Cindy van Roomen; Roelof Ottenhoff; Pilar Alfonso; Pilar Irún; Pilar Giraldo; Patrick Wisse; Clara Sá Miranda; Herman S Overkleeft; Johannes M Aerts
Journal:  Mol Genet Metab       Date:  2015-12-23       Impact factor: 4.797

3.  Delineating pathological pathways in a chemically induced mouse model of Gaucher disease.

Authors:  Ayelet Vardi; Hila Zigdon; Anna Meshcheriakova; Andrés D Klein; Chen Yaacobi; Raya Eilam; Brandon M Kenwood; Ahad A Rahim; Giulia Massaro; Alfred H Merrill; Einat B Vitner; Anthony H Futerman
Journal:  J Pathol       Date:  2016-07-05       Impact factor: 7.996

Review 4.  Palmitoylcarnitine, a surface-active metabolite.

Authors:  F M Goñi; M A Requero; A Alonso
Journal:  FEBS Lett       Date:  1996-07-15       Impact factor: 4.124

5.  The non-lysosomal β-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi.

Authors:  Heinz G Körschen; Yildiz Yildiz; Diana Nancy Raju; Sophie Schonauer; Wolfgang Bönigk; Vera Jansen; Elisabeth Kremmer; U Benjamin Kaupp; Dagmar Wachten
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

6.  Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes.

Authors:  Derek G Burke; Ahad A Rahim; Simon N Waddington; Stefan Karlsson; Ida Enquist; Kailash Bhatia; Atul Mehta; Ashok Vellodi; Simon Heales
Journal:  J Inherit Metab Dis       Date:  2012-11-15       Impact factor: 4.982

7.  Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher disease.

Authors:  Maria Fuller; Tina Rozaklis; Melanie Lovejoy; Krystyna Zarrinkalam; John J Hopwood; Peter J Meikle
Journal:  Mol Genet Metab       Date:  2007-12-26       Impact factor: 4.797

Review 8.  Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).

Authors:  Kathleen S Hruska; Mary E LaMarca; C Ronald Scott; Ellen Sidransky
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

Review 9.  Animal models for Gaucher disease research.

Authors:  Tamar Farfel-Becker; Einat B Vitner; Anthony H Futerman
Journal:  Dis Model Mech       Date:  2011-10-04       Impact factor: 5.758

10.  Accumulation of glucosylceramide in the absence of the beta-glucosidase GBA2 alters cytoskeletal dynamics.

Authors:  Diana Raju; Sophie Schonauer; Hussein Hamzeh; Kevin C Flynn; Frank Bradke; Katharina Vom Dorp; Peter Dörmann; Yildiz Yildiz; Christian Trötschel; Ansgar Poetsch; Bernadette Breiden; Konrad Sandhoff; Heinz G Körschen; Dagmar Wachten
Journal:  PLoS Genet       Date:  2015-03-24       Impact factor: 5.917

View more
  8 in total

Review 1.  Exploring genetic modifiers of Gaucher disease: The next horizon.

Authors:  Brad A Davidson; Shahzeb Hassan; Eric Joshua Garcia; Nahid Tayebi; Ellen Sidransky
Journal:  Hum Mutat       Date:  2018-09-11       Impact factor: 4.878

2.  Species-specific differences in nonlysosomal glucosylceramidase GBA2 function underlie locomotor dysfunction arising from loss-of-function mutations.

Authors:  Marina A Woeste; Sina Stern; Diana N Raju; Elena Grahn; Dominik Dittmann; Katharina Gutbrod; Peter Dörmann; Jan N Hansen; Sophie Schonauer; Carina E Marx; Hussein Hamzeh; Heinz G Körschen; Johannes M F G Aerts; Wolfgang Bönigk; Heike Endepols; Roger Sandhoff; Matthias Geyer; Thomas K Berger; Frank Bradke; Dagmar Wachten
Journal:  J Biol Chem       Date:  2019-01-20       Impact factor: 5.157

3.  A Small Molecule Fluorogenic Probe for the Detection of Sphingosine in Living Cells.

Authors:  Andrew K Rudd; Neel Mittal; Esther W Lim; Christian M Metallo; Neal K Devaraj
Journal:  J Am Chem Soc       Date:  2020-10-12       Impact factor: 15.419

4.  Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1.

Authors:  Manasa P Srikanth; Jace W Jones; Maureen Kane; Ola Awad; Tea Soon Park; Elias T Zambidis; Ricardo A Feldman
Journal:  Stem Cells Transl Med       Date:  2021-03-03       Impact factor: 6.940

Review 5.  The Enigmatic Role of GBA2 in Controlling Locomotor Function.

Authors:  Marina A Woeste; Dagmar Wachten
Journal:  Front Mol Neurosci       Date:  2017-11-28       Impact factor: 5.639

6.  Lipid⁻Protein Interactions in Niemann⁻Pick Type C Disease: Insights from Molecular Modeling.

Authors:  Simon Wheeler; Ralf Schmid; Dan J Sillence
Journal:  Int J Mol Sci       Date:  2019-02-07       Impact factor: 5.923

7.  Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.

Authors:  Mylene Huebecker; Elizabeth B Moloney; Aarnoud C van der Spoel; David A Priestman; Ole Isacson; Penelope J Hallett; Frances M Platt
Journal:  Mol Neurodegener       Date:  2019-11-08       Impact factor: 14.195

8.  Biochemical Characterization of the GBA2 c.1780G>C Missense Mutation in Lymphoblastoid Cells from Patients with Spastic Ataxia.

Authors:  Anna Malekkou; Maura Samarani; Anthi Drousiotou; Christina Votsi; Sandro Sonnino; Marios Pantzaris; Elena Chiricozzi; Eleni Zamba-Papanicolaou; Massimo Aureli; Nicoletta Loberto; Kyproula Christodoulou
Journal:  Int J Mol Sci       Date:  2018-10-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.